Pacesetter, Inc.

Josh Reiss

Xiaoyi Min

Gene A Bornzin

Jay Snell

Paul A Levine

Jong Gill

Peter Boileau

Mark William Kroll

Bing Zhu

Laleh Jalali

Mohssen Fard

An exemplary method includes receiving a signal from an intrathoracic vibration sensor, analyzing the signal for vibration associated with deceleration of blood flow into the left ventricle, based at least in part on the analyzing, deciding whether to call for adjustment to one or more parameters of a bi-ventricular pacing therapy. Other exemplary methods, devices, systems, etc., are also disclosed.

Use of cardiohemic vibration for pacing therapies

An exemplary method includes detecting a QRS complex using cutaneous electrodes, during the QRS complex, detecting an R-wave of a ventricle using an intracardiac electrode, determining if the R-wave occurred during a first, predetermined percentage of the QRS complex width and, based at least in part on the determining, deciding whether a patient is likely to respond to cardiac resynchronization therapy. Such a method may set the predetermined percentage to approximately 50%. An exemplary model includes a parameter for a percentage for the timing of an EGM R-wave with respect to the total width of an ECG QRS complex. Various other exemplary methods, devices, systems, etc. are also disclosed.

CRT responder model using EGM information

An implantable cardiac stimulation device provides stimulation therapy from within the left ventricle of a heart. The device includes a pulse generator adapted to be coupled to an implantable cardiac stimulation electrode and a power supply that provides the stimulation electrode with a positive voltage. The positive voltage promotes coating of the electrode through a body coating process. The coating serves to repel formation of clots on the electrode.

Left heart implantable cardiac stimulation system with clot prevention electrode body coating and method

Techniques are described for efficiently detecting and distinguishing among cardiac ischemia, hypoglycemia or hyperglycemia based on intracardiac electrogram (IEGM) signals. In one example, a preliminary indication of an episode of cardiac ischemia is detected based on shifts in ST segment elevation within the IEGM. In response, the implanted device then records additional IEGM data for transmission to an external system. The external system analyzes the additional IEGM data to confirm the detection of cardiac ischemia using a more sophisticated analysis procedure exploiting additional detection parameters. In particular, the external system uses detection parameters capable of distinguishing hypoglycemia, hyperglycemia and hyperkalemia from cardiac ischemia, such as QTmax and QTend intervals. Alternatively, the more sophisticated analysis procedure may be performed by the device itself, if it is so equipped. Other examples described herein pertain instead to the detection of atrial fibrillation.

System and method for efficiently distinguishing among cardiac ischemia, hypoglycemia and hyperglycemia using an implantable medical device and an external system

An implantable cardiac stimulation device prevents pacemaker mediated tachycardias during autocapture. The device includes a refractory circuit that establishes a lengthened post ventricular atrial refractory period (PVARP) in response to a lengthened AV interval. Such a lengthened AV interval may occur as a result of the provision of a back-up pacing pulse or fusion beat evaluation during autocapture.

Growing community of inventors

Kirkland, WA, United States of America

Josh Reiss